Janka Mátrai, Alessio Cantore, Cynthia C. Bartholomae, Andrea Annoni, Wei Wang, Abel Acosta‐Sanchez, Ermira Samara‐Kuko, Liesbeth De Waele, Ling Ma, Pietro Genovese, Martina Damo, Anne Arens, Kevin Goudy, Timothy C. Nichols, Christof von Kalle, Marinee K. L. Chuah, Maria Grazia Roncarolo, Manfred Schmidt, Thierry VandenDriessche, Luigi Naldini – 11 February 2011 – Lentiviral vectors are attractive tools for liver‐directed gene therapy because of their capacity for stable gene expression and the lack of preexisting immunity in most human subjects.

Prashant Bhangui, Eric Vibert, Pietro Majno, Chady Salloum, Paola Andreani, Joao Zocrato, Philippe Ichai, Faouzi Saliba, Rene Adam, Denis Castaing, Daniel Azoulay – 11 February 2011 – For patients who have cirrhosis with hepatocellular carcinoma (HCC), living donor liver transplantation (LDLT) reduces waiting time and dropout rates. We performed a comparative intention‐to‐treat analysis of recurrence rates and survival outcomes after LDLT and deceased donor liver transplantation (DDLT) in HCC patients.

Roger F. Butterworth – 11 February 2011 – Encephalopathy and brain edema are serious central nervous system complications of liver failure. Recent studies using molecular probes and antibodies to cell‐specific marker proteins have demonstrated the activation of microglial cells in the brain during liver failure and confirmed a central neuroinflammatory response.

Sandeep M. Patel, Seth Sweetser – 10 February 2011

Laura Lorenzon, Vincenzo Ziparo – 10 February 2011

Yong‐Ning Xin, Zhong‐Hua Lin, An‐Jin Chen, Shi‐Ying Xuan – 10 February 2011

Daniel Hartmann, Ujala Srivastava, Michaela Thaler, Karin N. Kleinhans, Gisèle N'Kontchou, Annika Scheffold, Kerstin Bauer, Ramona F. Kratzer, Natalia Kloos, Sarah‐Fee Katz, Zhangfa Song, Yvonne Begus‐Nahrmann, Alexander Kleger, Guido von Figura, Pavel Strnad, André Lechel, Cagatay Günes, Andrej Potthoff, Katja Deterding, Heiner Wedemeyer, Zhenyu Ju, Ge Song, Feng Xiao, Sonja Gillen, Hubert Schrezenmeier, Thomas Mertens, Marianne Ziol, Helmut Friess, Michael Jarek, Michael P. Manns, Michel Beaugrand, K.

Byoung Kwon Yoo, Prasanna K. Santhekadur, Rachel Gredler, Dong Chen, Luni Emdad, Sujit Bhutia, Lewis Pannell, Paul B. Fisher, Devanand Sarkar – 10 February 2011 – There is virtually no effective treatment for advanced hepatocellular carcinoma (HCC) and novel targets need to be identified to develop effective treatment. We recently documented that the oncogene Astrocyte elevated gene‐1 (AEG‐1) plays a seminal role in hepatocarcinogenesis.

Jung Min Lee, Sang Hoon Ahn, Hyon Suk Kim, Hana Park, Hye Young Chang, Do Young Kim, Seong Gyu Hwang, Kyu Sung Rim, Chae Yoon Chon, Kwang‐Hyub Han, Jun Yong Park – 10 February 2011 – Quantitative hepatitis B surface antigen (qHBsAg) and quantitative hepatitis B e antigen (qHBeAg) titers are emerging as useful tools for measuring viral loads and for predicting the virological response (VR) and serological response (SR) to pegylated interferon therapy. However, the clinical utility of these assays in patients taking entecavir (ETV) is largely unknown.

Luca Di Tommaso, Annarita Destro, Valentina Fabbris, Gaia Spagnuolo, Anna Laura Fracanzani, Silvia Fargion, Marco Maggioni, Carlo Patriarca, Roberto Maria Macchi, Michela Quagliuolo, Mauro Borzio, Massimo Iavarone, Angelo Sangiovanni, Massimo Colombo, Massimo Roncalli – 10 February 2011 – The American Association for the Study of Liver Diseases guidelines recommend the use of all available markers for improving the accuracy of the diagnosis of small hepatocellular carcinoma (HCC).